Cavitation Technologies, Inc. (CVAT) Announces Cross Licensing Agreement with CBDual Biotechnology Corp.

CHATSWORTH, CA / ACCESSWIRE / February 15, 2017 / Cavitation Technologies, Inc. (CTi) (OTCQB: CVAT) (Berlin:WTC) and CBDual Biotechnology Corp announced today that the two companies have reached a comprehensive cross-licensing agreement. This agreement covers intellectual property involving application of technology and process patents to produce high quality pharmaceutical grade cannabis materials. The patented technology facilitates the production of cannabinoid formulations that may include Cannabidiol (CBD) and Tetrahydrocannabinol (THC) that can be easily mixed into fluids or medications providing increased stability of products and a much quicker enhanced absorption rate of medications.

Dr. Greg Rubin, CEO of CBDual Biotechnology Corp. commented, “The cannabis derived products market is growing rapidly in North America. Market Research Future reports indicate that U.S., Canada, and Mexico are dominant markets for cannabis products and these markets are expected to grow at 33%

... read more at: